$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Type I hypersensitivity is mediated by antigen-induced cross-linking of IgE on the surface of mast cells and basophils. This results in cellular degranulation and the release of vasoactive and proinflammatory mediators such as histamine, tryptase, and platelet-activating factor2. Following the release of preformed mediators during degranulation, mast cells synthesize and release prostaglandins and leukotrienes, which further increase vascular permeability3. The initial clinical response occurs rapidly and is referred to as an “immediate reaction”. In the skin, a wheal-and-flare response is readily visible within minutes of antigen challenge. Depending on the dose of the challenge, it is possible to observe a “late phase response” a few hr later. Late phase swelling is due to localized edema and leukocyte recruitment into the tissues2. Histamine, generally considered to be the major mediator taking part in immediate allergic responses, acts on histamine receptor 1 (HR1) expressed on vessels and histamine receptor 2 (HR2) expressed on smooth muscle. The combined effect increases blood flow and vascular permeability at the site of inflammation4.
A variety of animal models of allergy have been developed in order to study the mechanisms involved in allergic inflammation, including models of allergic asthma, systemic anaphylaxis, and local anaphylaxis. Intravenous dye administration has been used to measure localized allergic responses in animal models for almost a century, with publications describing this technique dating back to the 1920s5. Rabbits and guinea pigs were the first animal models used to test immediate hypersensitivity reactions, and the most sensitive responses were generally found in the ear5,6. The assay was later validated for use in rats7 and mice8.
Historically, a variety of experimental methods have been used, including injection of antigen prior to injection of dye, injection of dye prior to injection of antigen, and simultaneous injection of dye and antigen. Intravenous dye administration as a means for measuring allergic responses is a versatile assay as it can be used for measuring active, passive, and reverse passive reactions5,9. Numerous dyes have been utilized to assess allergic responses, including Trypan Blue, Pontamine Sky Blue, Evans Blue, Geigy Blue 536, and India Ink5,6,9. A solution of 0.5% Evans Blue is currently the standard dye used for measuring allergic responses in the skin.
The anaphylactic response to challenge is transient; maximum intensity is reached within 10 - 15 min of dye injection, and no reaction is visible if dye is administered more than 30 min after challenge, regardless of the animal species used9. Quantification of dye extravasation was originally obtained by measuring wheal size as indicated by the blue dye7-9. Additionally, counts of degranulated mast cells can be quantified by excising skin tissue from the site of the reaction and staining with toluidine blue7. Mast cell degranulation is often used as a marker for cutaneous, IgE-mediated allergic responses, as mast cells are the main local cell population expressing the high affinity IgE receptor FcεRI. Spectrophotometric techniques for measuring dye extravasation into the tissue were developed for passive cutaneous anaphylaxis (PCA) in the rat10 and mouse11 in the 1990’s.
The following local anaphylaxis assay protocol was adapted from Kojima et al.1, and utilizes chicken egg ovalbumin (OVA) as the antigen for eliciting allergic responses. However, antigens other than OVA may be used if desired. The assay then uses Evans Blue dye to monitor changes in vascular permeability that occur due to mast cell IgE cross-linking and histamine release.